Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remibrutinib
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Remibrutinib is an investigational, orally administered **small-molecule Bruton's tyrosine kinase inhibitor** being developed by Novartis for immune-mediated diseases. It is designed as a highly selective BTK inhibitor and has been studied most prominently in chronic spontaneous urticaria, where phase 2 data and pooled safety analyses have suggested rapid symptom control and a generally favorable tolerability profile. Clinical development has also extended into multiple sclerosis, hidradenitis suppurativa, generalized myasthenia gravis, chronic inducible urticaria, peanut allergy, Sjogren's syndrome, and asthma, with several phase 3 programs reported. The drug is not identified in the provided material as an approved product or marketed brand.
- Brand names
- Rhapsido
- Other names
- remibrutinib
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on remibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remibrutinib.